ArticleEye (London, England)2025
Long-term effect of photodynamic therapy on choroidal vascularity index versus choroidal thickness as biomarkers for chronic central serous chorioretinopathy.
Article in Eye (London, England), 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Association of Retinal Pigment Epithelium Pump Function Reversal with Choroidal Vascularity Index in Treatment-Naïve Central Serous Chorioretinopathy.Ophthalmology science · 2026Article
- Three-Dimensional Choroidal Vessels Assessment in Fellow Eyes of Patients With Central Serous Chorioretinopathy.Translational vision science & technology · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectiveTo investigate the long-term impact of half-fluence photodynamic therapy (PDT) on chorioretinal architecture in chronic central serous chorioretinopathy (cCSCR) through novel choroidal vascularity index (CVI) versus previously established subfoveal choroidal thickness (SFCT).
methodsThis post-hoc analysis included prospectively collected swept-source optical coherence tomography (SS-OCT) images of a total of 29 cCSCR and fellow eyes (FE), acquired before, one and 12 months after PDT. CVI, total choroidal area (TCA), luminal area (LA) and stromal area (SA) were calculated using validated binarization technique. Central macular thickness (CMT), SFCT and subretinal fluid (SRF) were assessed. Longitudinal changes following PDT and associations between all parameters were investigated.
resultsCVI, TCA, LA, SFCT and CMT significantly decreased at month 1 (all p < 0.001). From month 1 to 12, CVI (p < 0.001) and LA (p = 0.01) increased but remained significantly lower than at baseline (p = 0.001 and p < 0.001). SFCT and CMT remained stable (all p = 1.0). SA and all FE parameters showed no significant changes at any time point. Comparing affected and FE, there were significant CVI differences at baseline (p < 0.001), month 1 (p = 0.01) and 12 (p < 0.001). SRF was significantly associated with higher CVI (p < 0.001), LA (p = 0.031), SFCT (p = 0.038).
conclusionHalf-fluence PDT significantly affects choroidal architecture, with sustained CVI and SFCT reductions 12 months post-treatment. Use of CVI as both a treatment response and disease activity marker is merited. There is a large discrepancy between CVI and SFCT, suggesting they each represent different anatomic responses. CVI proves to be a more specific and reliable CSCR biomarker than previously established SFCT.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.